

SCOPE: CCT, MatCh	
<b>MEDICATION:</b>	<b>PHENOBARBITAL</b>
<b>INTERVENTION:</b>	<p><u>Classification:</u> Anticonvulsant, Barbiturate</p> <p><u>Actions:</u> Long-acting barbiturate with sedative, hypnotic, and anticonvulsant properties. Depresses the sensory cortex, decreases motor activity, alters cerebellar function, and produces drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity; barbiturates produce dose-dependent respiratory depression</p> <p><u>Contraindications:</u></p> <ul style="list-style-type: none"> <li>• Hypersensitivity</li> <li>• Marked hepatic impairment</li> <li>• Dyspnea or airway obstruction</li> <li>• Porphyria (manifest and latent)</li> <li>• Intra-arterial/subcutaneous administration</li> <li>• Patients with a history of sedative/hypnotic addiction</li> </ul> <p><u>Precautions:</u></p> <ul style="list-style-type: none"> <li>• Renal or hepatic impairment</li> <li>• Respiratory depression</li> <li>• Severe anemia</li> <li>• Cardiac disease</li> <li>• Hemodynamically unstable</li> <li>• Diabetes</li> <li>• Hyperthyroidism</li> <li>• Hypoadrenalism</li> <li>• Febrile patients</li> <li>• May cause paradoxical responses, including agitation and hyperactivity, particularly in patients with acute or chronic pain and pediatric patients</li> <li>• <b>PREGNANCY RISK FACTOR: D</b></li> </ul> <p><u>Dosage:</u></p> <p>I. <u>Seizures:</u></p> <ol style="list-style-type: none"> <li>a. Pediatric (less than one year old):             <ol style="list-style-type: none"> <li>i. (IV/IO) 20mg/kg</li> </ol> </li> <li>b. Neonate:             <ol style="list-style-type: none"> <li>i. (IV/IO) 20mg/kg, repeat 10mg/kg x2 (max 40mg/kg)</li> </ol> </li> </ol> <p><u>Onset of Action:</u> 5 minutes</p> <p><u>Duration:</u> &gt;6 hours</p> <p><u>Adverse Effects:</u> Bradycardia, hypotension, syncope, thrombophlebitis, agitation, anxiety, ataxia, central nervous system stimulation or depression, confusion, dizziness, drowsiness, hallucination, hangover effect, headache, impaired judgement, insomnia, lethargy, nervousness, nightmares, nausea, vomiting, hyperkinesia, laryngospasm, apnea (especially with rapid IV use), hypoventilation, respiratory depression</p>

If this is a patient care policy, the information contained herein is used to provide guidance in the care of patients, but should not, and does not replace or preclude the use of clinical judgment.

<i>FOR OFFICE USE ONLY</i>	
Originator:	Original Date:
Revised Date:	
Effective Date: 06/01/18	Page 1 of 2

	<u>Special Considerations:</u> I. N/A
--	--